Skip to content

Study on the safety and effectiveness of intravenous injection of esketamine combined with propofol for gastroscopy in obese patients

Study on the safety and effectiveness of intravenous injection of esketamine combined with propofol for gastroscopy in obese patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045331
Enrollment
Unknown
Registered
2021-04-12
Start date
2021-04-12
Completion date
Unknown
Last updated
2021-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroscopy in obese patients

Interventions

Experience group:S-k group (esketamine group) : oral and pharyngeal surface anesthesia was performed with dacronine gum slurry. Then propofol 1.5mg/kg (fat removal weight) was slowly injected for 1min
Control group:R group (remifentanil group) : patients in both groups received oral and pharyngeal surface anesthesia with dacronine gum slurry. Then propofol 1.5mg/kg (fat removal weight) was slowly i

Sponsors

Department of Anesthesiology, Beijing Tsinghua Changgung Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.ASAI-III, patients undergoing painless gastroscopy; 2.Aged 18-50 years, BMI: 30-45 kg/m^2, systolic pressure 90-140mmhg, diastolic pressure 50-90mmhg, resting heart rate 50-100bpm, SpO2 >= 95% (no oxygen inhalation); 3.Malampati airway classification 80%.

Exclusion criteria

Exclusion criteria: 1.Patients refused to be included; 2.Allergic to the drugs (active ingredients or all excipients) used in this study; 3.He has epilepsy and other mental diseases, and has a history of addiction to analgesics such as opium and / or sedatives (sleeping pills); 4.Patients with severe risk of elevated blood pressure or intracranial pressure, poorly controlled or untreated hypertension (arterial hypertension, resting blood pressure >= 180 / 100mmhg); 5.Preeclampsia or eclampsia; 6.Hyperthyroidism without treatment or insufficient treatment; 7.Severe cardiac dysfunction: Patients with NYHA cardiac function grade 3-4, recent myocardial infarction or cerebral infarction, severe conduction block or malignant arrhythmia; 8.Renal failure (decreased glomerular filtration rate (GFR), endogenous creatinine clearance rate (Ccr) > 50mL / min; serum creatinine (Scr) 3) or persistent state of asthma.

Design outcomes

Primary

MeasureTime frame
Incidence of respiratory related adverse events requiring human intervention;Respiratory related adverse events;

Secondary

MeasureTime frame
modified observer’s assessment of alert /sedation, MOAA/S;Pain;

Countries

China

Contacts

Public ContactZhang Huan

Department of Anesthesiology, Beijing Tsinghua Changgung Hospital

zha00058@btch.edu.cn+86 13611326452

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026